Navigation Links
BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production
Date:6/29/2011

BALTIMORE, June 29, 2011 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of BD Recharge™, a chemically defined (CD) cell culture media supplement for biopharmaceutical manufacturing that offers productivity comparable to yeast-based peptones.

"Chemically defined supplements are a significant advance for biopharmaceutical cell culture," said Robert Hallenbeck, Vice President, BD Biosciences – Advanced Bioprocessing.  "BD Recharge provides performance comparable to undefined products, but with greater consistency, which means less risk and lower production costs for biopharmaceutical manufacturers."

The new BD Recharge cell culture media supplement, which was developed using CHO (Chinese hamster ovary) cell lines, eliminates unnecessary constituents to maximize cell viability and protein production.

Peptones are either animal-derived or animal-free supplements that are added to cell culture media to boost protein expression. Although peptones are highly effective, biopharmaceutical manufacturers are increasingly seeking CD alternatives to eliminate the variability and increased regulatory risk inherent in undefined materials.

BD Recharge is the first in a line of next-generation CD, animal-free supplements for the manufacture of biopharmaceuticals. BD Recharge is produced in the Company's fully dedicated animal-free/antibiotic-free (AF2™) facility, which sets a new standard for safety and quality for cell culture media. Products manufactured at the AF2 facility are controlled to the tertiary level — all ingredients, ingredient components and ingredient subcomponents used in the new facility are not of animal origin — significantly reducing the risks that can be associated with mixed-use facilities.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Alyssa Zeff
Public Relations
(201) 847-4358
Alyssa_Zeff@bd.com


'/>"/>
SOURCE BD
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Stanford professor honored for contributions to computational biosciences
2. Challenges for biofuels: New life cycle assessment report from Energy Biosciences Institute
3. Avantra Biosciences teams with TGen Drug Development to assist pharma
4. Human cells can copy not only DNA, but also RNA, says team from Pitt, Helicos BioSciences
5. InQ Biosciences Introduces First Fully Integrated Cell Research System
6. Energy Biosciences Institue named "Deal of Distinction" by tech-transfer group
7. Motorola Solutions Introduces Industrys Most Comprehensive Enterprise Device Management Platform
8. Elsevier introduces Protein Viewer, bringing science to life
9. Orbel Introduces the Board Shielding Wizard
10. Cermetek Introduces Medically Approved Modem Module
11. Olympus introduces the VisiGlide, a single-use guidewire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
(Date:2/15/2017)... ... ... Park Systems , a leader in Atomic Force Microscopy (AFM) since ... productivity with single click reliable nanoscale images, is now available on Park XE series ... the image once done manually by the operator producing high quality nanoscale imaging in ...
Breaking Biology Technology: